Loading
A phase 1 trial of SLV-324 run by Solve Therapeutics, now recruiting.
SLV-324 Treatment of Metastatic Solid Tumors is a phase 1 interventional study registered as NCT07108114 by Solve Therapeutics, with 70 participants planned, started 2025-08-25. Conditions recorded: Metastatic Solid Tumors. Interventions recorded: SLV-324 intravenous (IV infusion).
Shares Solve Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Solve Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/